Quality Systems – Page 83

Training records completed after deviation during QA review – inspection citation risk explained

Understanding the Risks of Completing Training Records Post-Deviation During QA Review In pharmaceutical manufacturing, maintaining rigorous adherence to Good Manufacturing Practices (GMP) is crucial for ensuring product quality and compliance.…

GDP errors repeated during inspection – QMS remediation failure

Case Study on Repeated GDP Errors During Inspections and QMS Remediation Failures In a recent inspection conducted by the FDA, a pharmaceutical manufacturing facility faced significant challenges due to recurring…

GDP errors repeated during deviation investigation – inspection citation risk explained

Understanding GDP Errors in Deviation Investigations: A Case Study for Regulatory Compliance Pharmaceutical manufacturing is fraught with complexities, and adherence to Good Documentation Practices (GDP) is critical for compliance, safety,…

GDP errors repeated during deviation investigation – CAPA and training system breakdown

Case Study: Analysis of Recurrent GDP Errors in a Deviation Investigation In the realm of pharmaceutical manufacturing, maintaining Good Documentation Practices (GDP) is crucial to ensure data integrity and compliance…

GDP errors repeated during inspection – inspection citation risk explained

A Case Study on Repeated GDP Errors During Inspection: Understanding Risks and Solutions In the high-stakes environment of pharmaceutical manufacturing, errors related to Good Documentation Practices (GDP) can lead to…

Personnel not trained on revised SOP during QA review – CAPA and training system breakdown

Case Study: Addressing Personnel Training Gaps on Revised SOPs During QA Review In the pharmaceutical manufacturing sector, adherence to Standard Operating Procedures (SOPs) is paramount for ensuring compliance, data integrity,…

Document revisions uncontrolled during deviation investigation – inspection citation risk explained

Uncontrolled Document Revisions During Deviation Investigations: Mitigating Inspection Risks The manufacturing of pharmaceuticals is a highly regulated and intricate process, where deviations can lead to significant regulatory scrutiny. This case…

Worst-case selection unjustified during multi-product manufacturing – cross-contamination risk case study

Case Study: Unjustified Worst-Case Selection Leading to Cross-Contamination in Multi-Product Manufacturing In pharmaceutical manufacturing, the risks associated with cross-contamination during multi-product manufacturing processes can lead to significant regulatory scrutiny and…

Cleaning validation not updated after product change during equipment changeover – revalidation CAPA failure

Failed Cleaning Validation Post Equipment Change: A Case Study in CAPA Management In pharmaceutical manufacturing, maintaining compliance with Good Manufacturing Practices (GMP) is critical for ensuring product quality and patient…

Carryover detected post-cleaning during inspection – regulatory observation analysis

Investigation of Carryover Detected After Cleaning: A Regulatory Perspective Regulatory observations can uncover significant challenges within pharmaceutical manufacturing environments. One such scenario involves the detection of material carryover post-cleaning during…

Worst-case selection unjustified during investigation – revalidation CAPA failure

Investigating Unjustified Worst-Case Selections in Pharma CAPA: A Case Study In pharmaceutical manufacturing, quality control failures can arise from a myriad of sources, often culminating in serious investigations and corrective…

Carryover detected post-cleaning during investigation – cross-contamination risk case study

Case Study on Detecting Carryover Post-Cleaning: Addressing Cross-Contamination Risks In the highly regulated realm of pharmaceutical manufacturing, maintaining product integrity is paramount. A recent incident in a medium-scale manufacturing facility…